These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17118124)

  • 1. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.
    Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R
    Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
    Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
    Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
    Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
    Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
    Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
    Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
    Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
    J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
    Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
    Buczko W; Hermanowicz JM
    Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
    J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
    Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
    Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
    Tapaninen T; Neuvonen PJ; Niemi M
    Eur J Clin Pharmacol; 2010 May; 66(5):497-502. PubMed ID: 20179914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversibility of the effects of aliskiren in the renal versus systemic circulation.
    Schneider MP; Janka R; Ziegler T; Raff U; Ritt M; Ott C; Veelken R; Uder M; Schmieder RE
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):258-64. PubMed ID: 22173856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
    Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
    J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren, the future of renin-angiotensin system blockade?
    Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
    Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
    Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
    Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
    Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren.
    Hong Y; Dingemanse J; Mager DE
    Clin Pharmacol Ther; 2008 Jul; 84(1):136-43. PubMed ID: 18288088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.